Curcumin and Inflammation in Non-alcoholic Fatty Liver Disease: a Randomized, Placebo Controlled Clinical Trial

Overview

Journal BMC Gastroenterol

Publisher Biomed Central

Specialty Gastroenterology

Date 2019 Jul 27

PMID 31345163

Citations 54

Authors

Saeede Saadati

Amir Sadeghi

Asieh Mansour

Zahra Yari

Hossein Poustchi

Mehdi Hedayati

Behzad Hatami

Azita Hekmatdoost

Affiliations

Soon will be listed here.

Abstract

Background: The aim of the present study was to evaluate the effects of curcumin supplementation on inflammatory indices, and hepatic features in patients with non-alcoholic fatty liver disease (NAFLD).

Methods: Fifty patients with NAFLD were randomized to receive lifestyle modification advice plus either 1500 mg curcumin or the same amount of placebo for 12 weeks.

Results: Curcumin supplementation was associated with significant decrease in hepatic fibrosis (p < 0.001), and nuclear factor-kappa B activity (p < 0.05) as compared with the baseline. Hepatic steatosis and serum level of liver enzymes, and tumor necrosis-α (TNF-α) significantly reduced in both groups (p < 0.05). None of the changes were significantly different between two groups.

Conclusion: Our results indicated that curcumin supplementation plus lifestyle modification is not superior to lifestyle modification alone in amelioration of inflammation.

Trial Registration: IRCT20100524004010N24, this trial was retrospectively registered on May 14, 2018.

Citing Articles

Natural Bioactive Compounds in the Management of Type 2 Diabetes and Metabolic (Dysfunction)-Associated Steatotic Liver Disease.

Ciobarca D, Catoi A, Gavrilas L, Banc R, Miere D, Filip L Pharmaceuticals (Basel). 2025; 18(2).

PMID: 40006091 PMC: 11859434. DOI: 10.3390/ph18020279.

Therapeutic Targets and Approaches to Manage Inflammation of NAFLD.

Geng W, Liao W, Cao X, Yang Y Biomedicines. 2025; 13(2).

PMID: 40002806 PMC: 11853636. DOI: 10.3390/biomedicines13020393.

Drug-Induced Liver Injury Associated with Turmeric and Piperine: A Case and Review.

Shrestha A, Elliott S, Abasszade J, Wu K, Worland T, Simpson I Case Rep Gastroenterol. 2025; 19(1):96-106.

PMID: 39995754 PMC: 11850025. DOI: 10.1159/000543679.

Evaluating Bioactive-Substance-Based Interventions for Adults with MASLD: Results from a Systematic Scoping Review.

Handu D, Stote K, Piemonte T Nutrients. 2025; 17(3).

PMID: 39940310 PMC: 11820841. DOI: 10.3390/nu17030453.

Therapeutic effects of curcumin supplementation on liver enzymes of nonalcoholic fatty liver disease patients: A systematic review and meta-analysis of randomized clinical trials.

Ebrahimzadeh A, Ebrahimzadeh A, Fooladshekan S, Mohseni S, Mohtashamian A, Babajafari S Food Sci Nutr. 2025; 13(1):e4144.

PMID: 39803230 PMC: 11716989. DOI: 10.1002/fsn3.4144.

References

Ainsworth B, Haskell W, Whitt M, Irwin M, Swartz A, Strath S . Compendium of physical activities: an update of activity codes and MET intensities. Med Sci Sports Exerc. 2000; 32(9 Suppl):S498-504. DOI: 10.1097/00005768-200009001-00009. View

Ziccardi P, Nappo F, Giugliano G, Esposito K, Marfella R, Cioffi M . Reduction of inflammatory cytokine concentrations and improvement of endothelial functions in obese women after weight loss over one year. Circulation. 2002; 105(7):804-9. DOI: 10.1161/hc0702.104279. View

Leclercq I, Farrell G, Sempoux C, Dela Pena A, Horsmans Y . Curcumin inhibits NF-kappaB activation and reduces the severity of experimental steatohepatitis in mice. J Hepatol. 2004; 41(6):926-34. DOI: 10.1016/j.jhep.2004.08.010. View

Cho J, Lee K, Kim C . Curcumin attenuates the expression of IL-1beta, IL-6, and TNF-alpha as well as cyclin E in TNF-alpha-treated HaCaT cells; NF-kappaB and MAPKs as potential upstream targets. Int J Mol Med. 2007; 19(3):469-74. View

Ramirez-Tortosa M, Ramirez-Tortosa C, Mesa M, Granados S, Gil A, Quiles J . Curcumin ameliorates rabbits's steatohepatitis via respiratory chain, oxidative stress, and TNF-alpha. Free Radic Biol Med. 2009; 47(7):924-31. DOI: 10.1016/j.freeradbiomed.2009.06.015. View

Shehzad A, Ha T, Subhan F, Lee Y . New mechanisms and the anti-inflammatory role of curcumin in obesity and obesity-related metabolic diseases. Eur J Nutr. 2011; 50(3):151-61. DOI: 10.1007/s00394-011-0188-1. View

Dattani J, Rajput D, Moid N, Highland H, George L, Desai K . Ameliorative effect of curcumin on hepatotoxicity induced by chloroquine phosphate. Environ Toxicol Pharmacol. 2011; 30(2):103-9. DOI: 10.1016/j.etap.2010.04.001. View

Malekzadeh R, Poustchi H . Fibroscan for assessing liver fibrosis: An acceptable alternative for liver biopsy: Fibroscan: an acceptable alternative for liver biopsy. Hepat Mon. 2011; 11(3):157-8. PMC: 3206683. View

Coban D, Milenkovic D, Chanet A, Khallou-Laschet J, Sabbe L, Palagani A . Dietary curcumin inhibits atherosclerosis by affecting the expression of genes involved in leukocyte adhesion and transendothelial migration. Mol Nutr Food Res. 2012; 56(8):1270-81. DOI: 10.1002/mnfr.201100818. View

10.

Alm-Eldeen A, Mona M, Shati A, El-Mekkawy H . Synergistic effect of black tea and curcumin in improving the hepatotoxicity induced by aflatoxin B1 in rats. Toxicol Ind Health. 2013; 31(12):1269-80. DOI: 10.1177/0748233713491807. View

11.

Ghaemi A, Taleban F, Hekmatdoost A, Rafiei A, Hosseini V, Amiri Z . How Much Weight Loss is Effective on Nonalcoholic Fatty Liver Disease?. Hepat Mon. 2013; 13(12):e15227. PMC: 3867211. DOI: 10.5812/hepatmon.15227. View

12.

Eslamparast T, Poustchi H, Zamani F, Sharafkhah M, Malekzadeh R, Hekmatdoost A . Synbiotic supplementation in nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled pilot study. Am J Clin Nutr. 2014; 99(3):535-42. DOI: 10.3945/ajcn.113.068890. View

13.

Panahi Y, Alishiri G, Parvin S, Sahebkar A . Mitigation of Systemic Oxidative Stress by Curcuminoids in Osteoarthritis: Results of a Randomized Controlled Trial. J Diet Suppl. 2015; 13(2):209-20. DOI: 10.3109/19390211.2015.1008611. View

14.

Byrne C, Targher G . NAFLD: a multisystem disease. J Hepatol. 2015; 62(1 Suppl):S47-64. DOI: 10.1016/j.jhep.2014.12.012. View

15.

Rahimlou M, Ahmadnia H, Hekmatdoost A . Dietary supplements and pediatric non-alcoholic fatty liver disease: Present and the future. World J Hepatol. 2015; 7(25):2597-602. PMC: 4635145. DOI: 10.4254/wjh.v7.i25.2597. View

16.

Maithilikarpagaselvi N, Sridhar M, Swaminathan R, Zachariah B . Curcumin prevents inflammatory response, oxidative stress and insulin resistance in high fructose fed male Wistar rats: Potential role of serine kinases. Chem Biol Interact. 2015; 244:187-94. DOI: 10.1016/j.cbi.2015.12.012. View

17.

Buzzetti E, Pinzani M, Tsochatzis E . The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metabolism. 2016; 65(8):1038-48. DOI: 10.1016/j.metabol.2015.12.012. View

18.

Kocher A, Bohnert L, Schiborr C, Frank J . Highly bioavailable micellar curcuminoids accumulate in blood, are safe and do not reduce blood lipids and inflammation markers in moderately hyperlipidemic individuals. Mol Nutr Food Res. 2016; 60(7):1555-63. DOI: 10.1002/mnfr.201501034. View

19.

Rahimlou M, Yari Z, Hekmatdoost A, Alavian S, Keshavarz S . Ginger Supplementation in Nonalcoholic Fatty Liver Disease: A Randomized, Double-Blind, Placebo-Controlled Pilot Study. Hepat Mon. 2016; 16(1):e34897. PMC: 4834197. DOI: 10.5812/hepatmon.34897. View

20.

Rahmani S, Asgary S, Askari G, Keshvari M, Hatamipour M, Feizi A . Treatment of Non-alcoholic Fatty Liver Disease with Curcumin: A Randomized Placebo-controlled Trial. Phytother Res. 2016; 30(9):1540-8. DOI: 10.1002/ptr.5659. View